EA200400565A1 - Конъюгаты химически модифицированного гормона роста человека - Google Patents

Конъюгаты химически модифицированного гормона роста человека

Info

Publication number
EA200400565A1
EA200400565A1 EA200400565A EA200400565A EA200400565A1 EA 200400565 A1 EA200400565 A1 EA 200400565A1 EA 200400565 A EA200400565 A EA 200400565A EA 200400565 A EA200400565 A EA 200400565A EA 200400565 A1 EA200400565 A1 EA 200400565A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemically modified
growth hormone
human growth
modified human
conjugates
Prior art date
Application number
EA200400565A
Other languages
English (en)
Other versions
EA008505B1 (ru
Inventor
Рори Ф. Финн
Уэй Лэйо
Нед Р. Сиджел
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200400565A1 publication Critical patent/EA200400565A1/ru
Publication of EA008505B1 publication Critical patent/EA008505B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

Согласно настоящему изобретению предложен химически модифицированный гормон роста человека (hGH), полученный путем связывания водорастворимого полимера с белком. Химически модифицированный белок по настоящему изобретению может иметь намного более продолжительную активность hGH, чем активность немодифицированного hGH, что дает возможность снизить дозу и создать благоприятные условия режима введения.Отчет о международном поиске был опубликован 2003.08.21.
EA200400565A 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека EA008505B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (2)

Publication Number Publication Date
EA200400565A1 true EA200400565A1 (ru) 2005-06-30
EA008505B1 EA008505B1 (ru) 2007-06-29

Family

ID=23295870

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200700431A EA200700431A1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека
EA200400565A EA008505B1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200700431A EA200700431A1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека

Country Status (25)

Country Link
EP (1) EP1453859A2 (ru)
JP (2) JP2005525302A (ru)
KR (2) KR20050044858A (ru)
CN (1) CN1608079A (ru)
AP (1) AP2004003050A0 (ru)
AU (1) AU2002356990A1 (ru)
BR (1) BR0214451A (ru)
CA (1) CA2467731A1 (ru)
CO (1) CO5580794A2 (ru)
EA (2) EA200700431A1 (ru)
EC (1) ECSP045114A (ru)
GE (1) GEP20063860B (ru)
HR (1) HRP20040448A2 (ru)
HU (1) HUP0500997A2 (ru)
IL (1) IL162031A0 (ru)
IS (1) IS7268A (ru)
MA (1) MA27544A1 (ru)
MX (1) MXPA04004809A (ru)
NO (1) NO20042182L (ru)
OA (1) OA13063A (ru)
PL (1) PL374354A1 (ru)
RS (1) RS53104A (ru)
TN (1) TNSN04090A1 (ru)
WO (1) WO2003044056A2 (ru)
ZA (1) ZA200403907B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003061577A2 (en) * 2002-01-18 2003-07-31 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
CA2498167C (en) 2002-09-09 2012-03-20 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
EP1673464A2 (en) * 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
BRPI0506864A (pt) * 2004-01-21 2007-05-29 Novo Nordisk As método para conjugar peptìdeos, peptìdeo conjugado, composto e sais, pró-drogas e solvatos farmaceuticamente aceitáveis destes, composição farmacêutica, uso de um composto, e, método para tratamento de doença
CN101010105A (zh) * 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法
WO2006073846A2 (en) * 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
SG158149A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
BRPI0615351A2 (pt) * 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag formulações lìquidas de hormÈnio do crescimento peguilado
CN104710503B (zh) * 2005-11-08 2023-04-25 Ambrx 公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
CA2882445A1 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008003750A2 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
WO2008049920A2 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
PL2272875T3 (pl) * 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
BRPI0911722B1 (pt) * 2008-07-31 2022-09-13 Pharmaessentia Corp Conjugado de peptídeo-polímero
BRPI0917000A2 (pt) 2008-08-06 2016-02-16 Novo Nordisk Healthcare Ag proteínas conjugadas com eficácia in vivo prolongada
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
WO2010030366A2 (en) * 2008-09-11 2010-03-18 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
WO2011146518A2 (en) * 2010-05-17 2011-11-24 Cebix Inc. Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
JP6820841B2 (ja) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション ペグ化インターフェロンのための投薬計画
KR20170125839A (ko) * 2015-03-11 2017-11-15 넥타르 테라퓨틱스 Ｉｌ-7 부분 및 중합체의 접합체
SG11201802180TA (en) * 2015-09-18 2018-04-27 Univ Miyazaki Long-acting adrenomedullin derivative
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE69128944T2 (de) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
BR0008759B1 (pt) * 1999-01-14 2014-03-11 Bolder Biotechnology Inc Métodos para a produção de proteinas contendo resíduos de cisteina livre
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
EP1352062A2 (en) * 2001-01-11 2003-10-15 Maxygen Aps Improved growth hormone molecules

Also Published As

Publication number Publication date
PL374354A1 (en) 2005-10-17
CO5580794A2 (es) 2005-11-30
AP2004003050A0 (en) 2004-06-30
JP2006321808A (ja) 2006-11-30
CA2467731A1 (en) 2003-05-30
ECSP045114A (es) 2004-07-23
AU2002356990A1 (en) 2003-06-10
MA27544A1 (fr) 2005-10-03
GEP20063860B (en) 2006-06-26
EA008505B1 (ru) 2007-06-29
OA13063A (en) 2006-11-10
EP1453859A2 (en) 2004-09-08
EA200700431A1 (ru) 2008-02-28
BR0214451A (pt) 2006-05-30
WO2003044056A2 (en) 2003-05-30
HRP20040448A2 (en) 2006-02-28
MXPA04004809A (es) 2004-08-11
ZA200403907B (en) 2007-12-27
IS7268A (is) 2004-05-17
WO2003044056A3 (en) 2003-08-21
IL162031A0 (en) 2005-11-20
RS53104A (en) 2006-10-27
CN1608079A (zh) 2005-04-20
KR20070072924A (ko) 2007-07-06
KR20050044858A (ko) 2005-05-13
TNSN04090A1 (fr) 2006-06-01
HUP0500997A2 (en) 2007-11-28
NO20042182L (no) 2004-08-11
JP2005525302A (ja) 2005-08-25

Similar Documents

Publication Publication Date Title
EA200400565A1 (ru) Конъюгаты химически модифицированного гормона роста человека
CY1106723T1 (el) Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
EP2829549A3 (en) Hybrid and tandem expression of neisserial derived proteins
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
EA200201214A1 (ru) Замещенные тиоацетамиды
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BR0208183A (pt) Peptìdeo modificado por wt1
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
RU2009105696A (ru) N-концевое полисиалилирование
DE60140426D1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
EP2279752A3 (en) Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
MXPA04000599A (es) Derivados del acido indan acetico y su uso como agentes pharmaceuticos, intermediarios, y metodo de preparacion.
EA200100905A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
MXPA05004993A (es) Conjugados de hormona del crecimiento humana modificados quimicamente.
EP1891954A3 (en) Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
EP2962699A3 (en) Improved method for preparing conjugates of proteins and chelating agents
EA200300852A1 (ru) Конъюгаты нейбластина с полимерами и способы их применения
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
TW200501963A (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
BR0211991A (pt) HormÈnio do crescimento humano modificado
FR2821359B1 (fr) L'heterocarpine, une proteine fixant le ghrh humain